TXG PE Ratio & Valuation, Is TXG Overvalued

Historical Valuation

10X Genomics Inc (TXG) is now in the Fair zone, suggesting that its current forward PS ratio of 2.27 is considered Fairly compared with the five-year average of -90.91. The fair price of 10X Genomics Inc (TXG) is between 17.32 to 174.29 according to relative valuation method.

Relative Value

Fair Zone

17.32-174.29

Current Price：20.46

Fair

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

Unlock 5-Year Valuation Change

Is 10X Genomics Inc (TXG) at a historical peak or a rare bargain? Access the full 5-year trend to find out.

Unlock Now

10X Genomics Inc (TXG) has a current Price-to-Book (P/B) ratio of 0.00. Compared to its 3-year average P/B ratio of 4.98, the current P/B ratio is approximately -100.00% higher. Relative to its 5-year average P/B ratio of 9.29, the current P/B ratio is about -100.00% higher. 10X Genomics Inc (TXG) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of -1.00%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of -1.65%, the current FCF yield is about -100.00% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for TXG competitors is 3.64, providing a benchmark for relative valuation. 10X Genomics Inc Corp (TXG.O) exhibits a P/S ratio of 2.27, which is -37.58% above the industry average. Given its robust revenue growth of 9.84%, this premium appears unsustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of TXG increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of TXG in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is TXG currently overvalued or undervalued?

What is 10X Genomics Inc (TXG) fair value?

TXG's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of 10X Genomics Inc (TXG) is between 17.32 to 174.29 according to relative valuation method.

How does TXG's valuation metrics compare to the industry average?

The average P/S ratio for TXG's competitors is 3.64, providing a benchmark for relative valuation. 10X Genomics Inc Corp (TXG) exhibits a P/S ratio of 2.27, which is -37.58% above the industry average. Given its robust revenue growth of 9.84%, this premium appears unsustainable.

What is the current P/B ratio for 10X Genomics Inc (TXG) as of Mar 11 2026?

As of Mar 11 2026, 10X Genomics Inc (TXG) has a P/B ratio of 0.00. This indicates that the market values TXG at 0.00 times its book value.

What is the current FCF Yield for 10X Genomics Inc (TXG) as of Mar 11 2026?

As of Mar 11 2026, 10X Genomics Inc (TXG) has a FCF Yield of 0.00%. This means that for every dollar of 10X Genomics Inc's market capitalization, the company generates 0.00 cents in free cash flow.

What is the current Forward P/E ratio for 10X Genomics Inc (TXG) as of Mar 11 2026?

As of Mar 11 2026, 10X Genomics Inc (TXG) has a Forward P/E ratio of -9.54. This means the market is willing to pay $-9.54 for every dollar of 10X Genomics Inc's expected earnings over the next 12 months.

What is the current Forward P/S ratio for 10X Genomics Inc (TXG) as of Mar 11 2026?

As of Mar 11 2026, 10X Genomics Inc (TXG) has a Forward P/S ratio of 2.27. This means the market is valuing TXG at $2.27 for every dollar of expected revenue over the next 12 months.

TXG Valuation